Roche Molecular Systems, Inc. Names Three Vice Presidents.
Martin D. Madaus, Joanne P. Spadoro, and David B. Thomas have been named vice presidents of Roche Molecular Systems, Inc.
The announcement was made by Kathy Ordonez, president of the biotechnology company.
Martin D. Madaus, PhD, is the new vice president of business development for blood screening. In mid-1997, Roche entered the blood and plasma screening market with products using polymerase chain reaction (PCR) technology. "We plan to market fully automated screening systems that can simultaneously test for several viruses," said Ordonez. "Martin Madaus's leadership, scientific, and communication skills make him the ideal person to exercise global oversight of all business activities in support of the blood screening program." Madaus served most recently as president and general manager of Roche Diagnostics-Canada. He earned his PhD in veterinary medicine at the University of Hannover, Germany.
Joanne P. Spadoro, PhD, has been named vice president, operations. Spadoro joined Roche Molecular Systems, Inc., in 1990 as a senior scientist for diagnostic development. In 1997, she became director, diagnostic development, and was responsible for the development of the AMPLICOR(R) and COBAS(R) PCR-based diagnostic products for the detection of infectious pathogens. Spadoro served most recently as director, blood screening development, and senior director, operations. She earned her bachelor's degree from Douglas College, New Brunswick, N.J., and her doctorate at the University of Connecticut. She is a member of the American Society for Testing and Materials, and of the American Society for Microbiology.
"Joanne Spadoro's extensive knowledge of the AMPLICOR(R) product line, her strong management skills, and recent experience in manufacturing will serve her well in this new capacity," said Ordonez.
David B. Thomas has joined Roche Molecular Systems, Inc. as vice president for regulatory and clinical affairs. "His responsibilities will encompass oversight of all global regulatory and clinical trial activities for our organization," said Ordonez, "including interface with the Food and Drug Administration and support for all outside the U.S. product registrations."
Thomas has broad experience in clinical trials, regulatory affairs and quality management, having held lead positions in these areas with DepoTech Corporation, Ares-Serono, and Pfizer. He has managed the design and execution of clinical studies and the registration of both pharmaceutical and diagnostic products. Thomas holds a master's degree in human biology with a concentration in biostatistics from the University of California, Los Angeles. He is a member of the Regulatory Affairs Professional Society and the Food and Drug Law Institute. Previously, he held key assignments with the Health Industry Manufacturing Agency (HIMA), including chairman of the Drug/Device Task Force.
The Roche Group is a world leader in research-based healthcare with principal business in pharmaceuticals, diagnostics, vitamins, fragrances and flavors. Through the company's Diagnostic Division, innovative testing products and services are made available to physicians, patients, hospitals and laboratories worldwide.
Roche Molecular Systems, Inc., Pleasanton, California, USA, a business unit within Roche Diagnostics, develops, manufacturers and oversees the commercialization of PCR nucleic acid amplification-based test kits marketed under the trade name AMPLICOR(R).
|Printer friendly Cite/link Email Feedback|
|Date:||Jun 21, 1999|
|Previous Article:||Multex.com News - Multex.com Stock Snapshot - Phoenix Technologies Ltd. PTEC.|
|Next Article:||Grass to Introduce Revolutionary Sleep Study Product at the APSS Meeting in Orlando, FL.|